Electrocardiogram Analysis in COVID-19 Patients

SARS-CoV Infection Clinical Trial

— ELCOVID  

Official title:

Electrocardiogram Analysis in COVID-19 Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04367129
• Other study ID #: 385/2020/Oss/AOUFe
• Status: Recruiting
• Start date: April 14, 2020
• Est. completion date: April 1, 2021

Study information

• Verified date: April 2020
• Source: University Hospital of Ferrara
• Contact: Matteo Bertini, MD, PhD
• Phone: +393474010904
• Email: doc.matber[@]gmail.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Electrocardiographic (ECG) evaluation of patients with severe acute respiratory syndrome coronavirus 2 (SARS-Cov-2) infection. The present study involves three different phases of evaluation of the ECG traces of hospitalized patients with SARS-CoV-2 infection. - Phase 1: it is proposed to collect and retrospectively analyze the ECGs of hospitalized patients with severe SARS-CoV-2 infection which led to invasive ventilation or patient death as a consequence and, if available, also possible troponin dosage; - Phase 2: aims to collect and analyze the ECGs of consecutive hospitalized patients with SARS-CoV-2 infection and evaluate their relationship with the course of the disease, cardiac involvement and prognosis; - Phase 3: it is proposed to repeat ECG and to carry out echocardiogram to patients with SARS-CoV-2 infection after 3 months from hospital discharge by simultaneously performing, if deemed clinically indicated, also cardiac magnetic resonance. In this phase, any evolutions of ECG alterations of the acute phase will be described and the relationship with cardiac involvement will be assessed.

Description:

In the early months of 2020, SARS-CoV-2 virus infection quickly spread around the world to a pandemic. On 2 April 2020, confirmed cases of coronavirus disease 2019 (COVID-19) worldwide exceeded one million and an unprecedented health crisis has occurred in recent history. SARS-CoV-2 disease can lead to the development of even severe pneumonia with the need for ventilatory support and in some cases fatal outcome. From the data currently present in the literature, important relationships emerge between infection and cardiovascular diseases. COVID-19 patients with underlying pre-existing heart disease or cardiovascular risk factors have a more severe course of the disease and are more at risk of adverse outcomes and death than individuals with no history of heart disease or risk factors. During the course of the infection, some patients even without previous heart disease may experience myocardial injury and this leads to a significant increase in in-hospital mortality. Myocardial pain during SARS-CoV-2 infection is associated with cardiac dysfunction and arrhythmias. To date, there are no data on the role of the electrocardiogram neither in the diagnosis of cardiac involvement nor in predicting the prognosis of patients with SARS-CoV-2 infection. Whether there are basal electrocardiographic features capable of correlating with the course of the disease and the prognosis is currently unknown. The development of electrocardiographic changes during the course of the disease and their possible prognostic significance has not currently been described. The present study involves three different phases of evaluation of the electrocardiographic (ECG) traces of hospitalized patients with SARS-CoV-2 infection. - Phase 1: it is proposed to collect and retrospectively analyze the ECGs of hospitalized patients with severe SARS-CoV-2 infection which led to invasive ventilation or patient death as a consequence and, if available, also possible troponin dosage; - Phase 2: aims to collect and analyze the ECGs of consecutive hospitalized patients with SARS-CoV-2 infection and evaluate their relationship with the course of the disease, cardiac involvement and prognosis; - Phase 3: it is proposed to repeat ECG and to carry out echocardiogram to patients with SARS-CoV-2 infection after 3 months from hospital discharge by simultaneously performing, if deemed clinically indicated, also cardiac magnetic resonance. In this phase, any evolutions of ECG alterations of the acute phase will be described and the relationship with cardiac involvement will be assessed. Phase 1 Retrospective, multicentric, cohort study Phase 2 and 3 prospective, multicentric, cohort study Phase 1: • Describe the ECG characteristics in patients presenting with severe form of SARS-CoV-2 infection Phase 2: - To evaluate the correlation between ECG signs and cardiac involvement in the acute phase - Assess the correlation between ECG signs and mortality/invasive mechanical ventilation in the acute phase secondary: - To evaluate the prevalence of ECG changes in the enrolled population - Analyze the prevalence of various cardiovascular risk factors in the enrolled population - Examine the impact of ECG changes on the short-term prognosis - Explore new possible prognostic risk factors Phase 3: - To evaluate the correlation between acute phase ECG signs and chronic phase cardiac involvement - To evaluate the appearance, in the short-term follow-up, of signs of cardiac involvement (cardiomyopathies and conduction disorders in particular) Data collected: - demographic characteristics - cardiovascular risk factors - comorbidities - blood tests including cardiac markers (troponin, BNP) collected in multiple points if available - radiographic examinations and echocardiogram (if performed) - ECG traces performed at onset, worsening and / or troponin peak - length of hospital stay - treatments administered - complications - clinical outcome Enrolled patients will be followed clinically until the day of discharge as per care practice. A 3-month follow-up is foreseen to evaluate the outcome and repeat the ECG. At the discretion of the clinician who manages the patient, transthoracic echocardiogram and / or cardiac magnetic resonance imaging will also be performed. A formal calculation of the sample size is not possible due to the total lack of data. Furthermore, since it is an observational project, the calculation of the sample size is not mandatory. However, based on similar studies, it is believed that the minimum samples for the various phases are: 80 patients for Phase 1 study objectives, 800 patients for Phase 2 study objectives and 300 patients for Phase 3 study objectives

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1014
• Est. completion date: April 1, 2021
• Est. primary completion date: April 1, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 100 Years

Eligibility

Inclusion Criteria:

• age >18 years old
• confirmed SARS-CoV-2 infection (pharyngeal swab positive for viral RNA or clinical diagnosis of COVID-19 based on chest x-ray or high resolution CT)
• hospitalization in a hospital setting

Exclusion Criteria:

• SARS-CoV-2 infection not confirmed by pharyngeal swab or clinical-radiographic criteria
• absence of ECG tracing performed at the time of hospitalization

Related Conditions & MeSH terms

• Coronavirus Infections
• SARS-CoV Infection
• Severe Acute Respiratory Syndrome

Intervention

Diagnostic Test:
• ECG
12 lead electrocardiogram

Locations

Country	Name	City	State
Italy	Arcispedale S. Anna	Ferrara

Sponsors (1)

Lead Sponsor	Collaborator
University Hospital of Ferrara

Country where clinical trial is conducted

Italy, 

References & Publications (4)

Bonow RO, Fonarow GC, O'Gara PT, Yancy CW. Association of Coronavirus Disease 2019 (COVID-19) With Myocardial Injury and Mortality. JAMA Cardiol. 2020 Jul 1;5(7):751-753. doi: 10.1001/jamacardio.2020.1105. — View Citation

Chen N, Zhou M, Dong X, Qu J, Gong F, Han Y, Qiu Y, Wang J, Liu Y, Wei Y, Xia J, Yu T, Zhang X, Zhang L. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet. 2020 Feb 15;395(10223):507-513. doi: 10.1016/S0140-6736(20)30211-7. Epub 2020 Jan 30. — View Citation

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T, Wang H, Wan J, Wang X, Lu Z. Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020 Jul 1;5(7):811-818. doi: 10.1001/jamacardio.2020.1017. Erratum in: JAMA Cardiol. 2020 Jul 1;5(7):848. — View Citation

Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol. 2020 May;17(5):259-260. doi: 10.1038/s41569-020-0360-5. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Phase 1: ECG characteristics in patients presenting with severe form of SARS-CoV-2 infection	Describe the ECG characteristics in patients presenting with severe form of SARS-CoV-2 infection	1 month
Primary	Phase 2: Correlation between ECG signs and needs for invasive mechanical ventilation and/or mortality in the acute phase	To evaluate the correlation between ECG signs and cardiac involvement in the acute phase; • Assess the correlation between ECG signs and mortality in the acute phase	6 months
Primary	Phase 3: Correlation between ECG signs and cardiac involvement and mortality in the chronic phase	To evaluate the correlation between acute phase ECG signs and chronic phase cardiac involvement; • evaluate the appearance, in the short-term follow-up, of signs of cardiac involvement (cardiomyopathies and conduction disorders in particular)	12 months